Featured Articles
-
100% Drug Tariffs Are A Dire Threat — And Patients Can't Wait
10/15/2025
Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, writes BioNJ president and CEO Debbie Hart.
-
Patients And Industry Need A New Model For Rare Disease Gene Therapy
10/10/2025
October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug development model, writes Silvia Cerolini.
-
Partnering To Commercialize Radiopharmaceuticals
10/9/2025
For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new products.
-
Why I Love Working With Leaders Who Have 'Rounded Corners'
10/6/2025
Life science leaders with 'rounded corners' lead to more enduring progress than razor-sharp perfection ever could, writes Tara Miller, founding partner at Artemis Factor.
-
An Updated View Of The Federal Segment: Access Levers For Manufacturers
10/2/2025
The third and final part of a series aimed at helping drug and device makers navigate the U.S. Veterans Affairs and Department of Defense health systems.
-
Early-Stage Life Sciences Partnerships Raise Later-Stage Considerations
9/25/2025
Emerging biotechs and their investors are exploring partnerships with drug companies at much earlier stages. Experts at Sidley Austin discuss key considerations for structuring partnership agreements.
-
Pharma Direct-To-Patient 2.0: From Experiment To Imperative
9/23/2025
Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access, according to Deepak Thomas and Sari Kaganoff.
-
Strategic Approaches To Reducing Legal Spend Without Compromising Quality
9/19/2025
Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences companies real money on legal expenses, writes Snell & Wilmer's April Wurster.
-
RFK Jr. Wants Every American Wearing A Wearable. How Can Pharma Build A Business Around It?
9/16/2025
The timing is now for pharma to be all-in on using wearables as their new business strategy, says Digital Medicine Society (DiMe) Director of Partnerships Smit Patel, PharmD.
-
The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery
9/11/2025
Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around.